Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MYNZ
stocks logo

MYNZ

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
250.00K
+37.61%
-4.400
-71.79%
Estimates Revision
The market is revising No Change the revenue expectations for Mainz Biomed N.V. (MYNZ) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -28.22%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-28.22%
In Past 3 Month
Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.170
sliders
Low
14.00
Averages
14.00
High
14.00
Current: 1.170
sliders
Low
14.00
Averages
14.00
High
14.00
Maxim Group
Michael Okunewitch
Strong Buy
Initiates
$14
2025-02-14
Reason
Maxim Group
Michael Okunewitch
Price Target
$14
2025-02-14
Initiates
Strong Buy
Reason
Maxim initiated coverage of Mainz Biomed with a Buy rating and $14 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mainz Biomed NV (MYNZ.O) is -0.56, compared to its 5-year average forward P/E of -2.55. For a more detailed relative valuation and DCF analysis to assess Mainz Biomed NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.55
Current PE
-0.56
Overvalued PE
0.07
Undervalued PE
-5.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
55.39
Current PS
0.00
Overvalued PS
135.35
Undervalued PS
-24.56
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MYNZ News & Events

Events Timeline

(ET)
2025-12-02
08:31:00
Mainz Biomed Adds ColoAlert Test to DoctorBox Portfolio
select
2025-11-18 (ET)
2025-11-18
09:29:29
Mainz Biomed and OncoVanguard8 Partner to Introduce ColoAlert in South America
select
2025-10-08 (ET)
2025-10-08
09:03:11
Mainz Biomed announces findings from biomarker panel feasibility study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-02Globenewswire
Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany
  • Market Expansion: Mainz Biomed's ColoAlert® test has been integrated into DoctorBox, a leading digital health platform in Germany, marking a significant milestone in the company's European growth strategy and expected to greatly enhance access to early cancer detection.
  • User Base: With over one million registered users and more than ten million test results, the integration of ColoAlert® will further solidify DoctorBox's leadership in digital preventive healthcare, driving business growth for Mainz Biomed.
  • Innovative Collaboration: The partnership with DoctorBox not only lowers barriers to colorectal cancer screening but also enhances user engagement through at-home testing, aligning with modern healthcare service trends.
  • Importance of Preventive Care: With approximately 60,000 new colorectal cancer cases diagnosed annually in Germany, the introduction of ColoAlert® provides an effective early detection solution to meet this demand, further advancing the development of personalized preventive healthcare.
[object Object]
Preview
7.5
12-02Newsfilter
Mainz Biomed Partners with DoctorBox to Launch ColoAlert Test in Germany
  • Market Expansion: Mainz Biomed's ColoAlert test has been added to DoctorBox's portfolio, marking a significant milestone in the company's European growth strategy and is expected to greatly enhance access to early cancer detection.
  • Collaborative Advantage: By partnering with DoctorBox, Mainz Biomed can offer ColoAlert testing in home settings, lowering barriers to colorectal cancer screening and driving innovation in preventive medicine.
  • User Base: With over one million registered users and more than ten million test results transmitted, DoctorBox's extensive user base will provide robust support for the promotion of ColoAlert, further enhancing the company's influence in the digital health sector.
  • New Standard in Preventive Healthcare: The integration of ColoAlert into DoctorBox's digital platform will make it a cornerstone of next-generation preventive healthcare services, improving user health management experiences significantly.
[object Object]
Preview
7.5
11-18Newsfilter
Mainz Biomed and OncoVanguard8 Partner to Introduce ColoAlert in South America

  • Collaboration Announcement: Mainz Biomed has signed a Memorandum of Understanding with OncoVanguard8 to introduce its DNA-based colorectal cancer screening test, ColoAlert®, to South America, starting with Peru.

  • Colorectal Cancer Statistics: Colorectal cancer is highly prevalent and preventable, with around 17,000 new cases diagnosed annually in Peru, Colombia, and Ecuador, emphasizing the need for effective early detection strategies.

  • Market Strategy: The MOU outlines commercial, legal, and regulatory terms, along with a go-to-market strategy, with plans for a final distribution agreement to be signed soon.

  • Company Backgrounds: Mainz Biomed specializes in molecular genetic diagnostics for cancer, while OncoVanguard8 focuses on innovative healthcare solutions in Latin America, aiming to enhance cancer prevention and early detection.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mainz Biomed NV (MYNZ) stock price today?

The current price of MYNZ is 1.17 USD — it has increased 0.86 % in the last trading day.

arrow icon

What is Mainz Biomed NV (MYNZ)'s business?

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

arrow icon

What is the price predicton of MYNZ Stock?

Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mainz Biomed NV (MYNZ)'s revenue for the last quarter?

Mainz Biomed NV revenue for the last quarter amounts to 214.76K USD, decreased % YoY.

arrow icon

What is Mainz Biomed NV (MYNZ)'s earnings per share (EPS) for the last quarter?

Mainz Biomed NV. EPS for the last quarter amounts to -0.27 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Mainz Biomed NV (MYNZ)'s fundamentals?

The market is revising No Change the revenue expectations for Mainz Biomed N.V. (MYNZ) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -28.22%.
arrow icon

How many employees does Mainz Biomed NV (MYNZ). have?

Mainz Biomed NV (MYNZ) has 19 emplpoyees as of December 05 2025.

arrow icon

What is Mainz Biomed NV (MYNZ) market cap?

Today MYNZ has the market capitalization of 9.96M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free